• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket

    9/22/22 6:34:35 AM ET
    $ACOR
    $AVCT
    $BEAT
    $BNRG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    EDP Services
    Technology
    Get the next $ACOR alert in real time by email

    Gainers

    • Spero Therapeutics, Inc. (NASDAQ:SPRO) rose 105.6% to $1.69 in pre-market trading. GSK and Spero Therapeutics announced exclusive license agreement for late-stage antibiotic asset, Tebipenem HBr.
    • HeartBeam, Inc. (NASDAQ:BEAT) shares rose 27.8% to $2.02 in pre-market trading after dropping 16% on Wednesday. Heartbeam recently announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome and cardiac arrhythmia was issued by the USPTO.
    • American Virtual Cloud Technologies, Inc. (NASDAQ:AVCT) rose 20.1% to $0.2590 in pre-market trading.
    • Taoping Inc. (NASDAQ:TAOP) rose 19.7% to $0.73 in pre-market trading. Taoping recently posted 1H revenue of $10.5 million.
    • Acorda Therapeutics, Inc. (NASDAQ:ACOR) rose 18.4% to $0.3672 in pre-market trading after declining around 7% on Wednesday.
    • Lytus Technologies Holdings PTV. Ltd. (NASDAQ:LYT) rose 15.8% to $1.90 in pre-market trading after dropping over 5% on Wednesday.
    • Organovo Holdings, Inc. (NASDAQ:ONVO) rose 15.3% to $2.45 in pre-market trading.
    • Ensysce Biosciences, Inc. (NASDAQ:ENSC) rose 12% to $0.2660 in pre-market trading after declining 5% on Wednesday.
    • Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) rose 11.2% to $1.98 in pre-market trading after declining over 4% on Wednesday.
    • Timber Pharmaceuticals, Inc. (NYSE:TMBR) rose 10.3% to $0.1138 in pre-market trading. Timber Pharmaceuticals recently received positive opinion on Orphan Designation from European Medicines Agency For TMB-001.
    • SmartRent, Inc. (NYSE:SMRT) rose 8.1% to $2.93 in pre-market trading after gaining around 7% on Wednesday.
    • Deutsche Bank Aktiengesellschaft (NYSE:DB) rose 6.3% to $9.14 in pre-market trading. Deutsche Bank said its New York Branch, Deutsche Bank New York, and its affiliate Deutsche Bank Trust Company Americas have raised their prime lending from 5.50% to 6.25%.

     

    Don’t forget to check out our premarket coverage here .

    Losers

    • Soluna Holdings, Inc. (NASDAQ:SLNH) fell 11.9% to $1.48 in pre-market trading after gaining around 6% on Wednesday.
    • Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares fell 11.6% to $0.6899 in pre-market trading after jumping 10% on Wednesday. Tiziana Life Sciences announced purchase of 20,145 common shares by Executive Chairman.
    • ECMOHO Limited (NASDAQ:MOHO) fell 9.4% to $0.1580 in pre-market trading after jumping over 50% on Wednesday.
    • China Pharma Holdings, Inc. (NYSE:CPHI) shares fell 8.6% to $0.1411 in pre-market trading.
    • Evaxion Biotech A/S (NASDAQ:EVAX) fell 8.5% to $2.13 in pre-market trading. Evaxion Biotech shares gained 14% on Wednesday after the company announced it reached an important milestone announcing today that it had enrolled its first patient in the global phase 2b clinical trial of EVX-01.
    • Brenmiller Energy Ltd (NASDAQ:BNRG) fell 7.7% to $3.56 in pre-market trading.
    • FOXO Technologies Inc. (NYSE:FOXO) fell 7.1% to $2.08 in pre-market trading after gaining over 6% on Wednesday.
    • Novavax, Inc. (NASDAQ:NVAX) fell 5.3% to $24.50 in pre-market trading. JP Morgan downgraded Novavax from Neutral to Underweight and lowered the price target from $132 to $27.
    • Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares fell 4.3% to $5.56 in pre-market trading after declining 5% on Wednesday.
    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $AVCT
    $BEAT
    $BNRG

    CompanyDatePrice TargetRatingAnalyst
    Evaxion A/S
    $EVAX
    2/19/2026$10.00Buy
    Maxim Group
    Soluna Holdings Inc.
    $SLNH
    12/11/2025$5.00Neutral → Buy
    H.C. Wainwright
    Heartbeam Inc.
    $BEAT
    12/11/2025$8.00Speculative Buy → Buy
    The Benchmark Company
    Heartbeam Inc.
    $BEAT
    12/8/2025$2.50Buy
    H.C. Wainwright
    Heartbeam Inc.
    $BEAT
    10/31/2025$4.00Buy
    Roth Capital
    Novavax Inc.
    $NVAX
    10/24/2025$18.00Overweight
    Cantor Fitzgerald
    Ocular Therapeutix Inc.
    $OCUL
    9/15/2025$21.00Buy
    Chardan Capital Markets
    Novavax Inc.
    $NVAX
    8/28/2025$10.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACOR
    $AVCT
    $BEAT
    $BNRG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Evaxion Biotech with a new price target

    Maxim Group initiated coverage of Evaxion Biotech with a rating of Buy and set a new price target of $10.00

    2/19/26 8:24:06 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Soluna Holdings upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Soluna Holdings from Neutral to Buy and set a new price target of $5.00

    12/11/25 8:46:07 AM ET
    $SLNH
    EDP Services
    Technology

    HeartBeam upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded HeartBeam from Speculative Buy to Buy and set a new price target of $8.00

    12/11/25 8:45:10 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $ACOR
    $AVCT
    $BEAT
    $BNRG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lindstrom Richard L Md bought $461,354 worth of shares (60,229 units at $7.66), increasing direct ownership by 32% to 246,933 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/24/26 6:13:03 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Martell Frank bought $103,244 worth of shares (50,000 units at $2.06) (SEC Form 4)

    4 - SmartRent, Inc. (0001837014) (Issuer)

    12/16/25 4:30:22 PM ET
    $SMRT
    EDP Services
    Technology

    Chief Executive Officer Martell Frank bought $103,458 worth of shares (50,000 units at $2.07) (SEC Form 4)

    4 - SmartRent, Inc. (0001837014) (Issuer)

    12/12/25 5:31:56 PM ET
    $SMRT
    EDP Services
    Technology

    $ACOR
    $AVCT
    $BEAT
    $BNRG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ACOR
    $AVCT
    $BEAT
    $BNRG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA

    BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces positive new biomarker data from a late-breaking poster titled "Nasal foralumab downregulates CSF inflammation and upregulates CSF neuroprotective proteomic pathways which correlate with [F-18]PBR06-PET imaging in na-SPMS with PIRA," which was presented by investigators from Brigham and Women's Hospital, Boston, MA. In multiple sclerosis (MS), an autoimmune disease involving inflammation, demyelination, and neurodegeneration in the CNS, Cerebrospinal fluid (CSF)

    2/25/26 7:00:00 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ to Participate in March Investor Conferences

    BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in several upcoming investor conferences in March 2026. TD Cowen 46th Annual Health Care Conference:Date: Monday, March 2, 2026Fireside Chat: 9:10 – 9:40 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Boston, MA Jefferies Biotech on the Beach Summit:Date: Tuesday, March 10, 2026Location: Miami, FL Citizens Life Sciences Conference 2026:Date: Wednesday, March 11, 2026Fireside Chat: 9:00 – 9:25 AM ETPresenter: Pravin U

    2/24/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations

    Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to host an investor webcast on Monday, March 2, 2026, at 7:30 AM ET to discuss the Macula Society presentations BEDFORD, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will present detailed results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), at the 49th Macula Soc

    2/23/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

    For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

    10/3/23 2:56:27 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ACOR
    $AVCT
    $BEAT
    $BNRG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Waheed Nadia sold $27,167 worth of shares (3,510 units at $7.74), decreasing direct ownership by 1% to 314,907 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/24/26 6:13:43 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lindstrom Richard L Md bought $461,354 worth of shares (60,229 units at $7.66), increasing direct ownership by 32% to 246,933 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/24/26 6:13:03 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Notman Donald sold $103,472 worth of shares (11,446 units at $9.04), decreasing direct ownership by 3% to 366,356 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/17/26 8:31:05 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AVCT
    $BEAT
    $BNRG
    SEC Filings

    View All

    SEC Form 6-K filed by Tiziana Life Sciences Ltd.

    6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)

    2/25/26 7:00:10 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form F-3 filed by Brenmiller Energy Ltd

    F-3 - Brenmiller Energy Ltd. (0001901215) (Filer)

    2/23/26 4:46:47 PM ET
    $BNRG
    Building Products
    Industrials

    SEC Form S-8 filed by Tiziana Life Sciences Ltd.

    S-8 - Tiziana Life Sciences Ltd (0001723069) (Filer)

    2/20/26 4:10:50 PM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AVCT
    $BEAT
    $BNRG
    Leadership Updates

    Live Leadership Updates

    View All

    HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer

    Brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies Will initially focus on launching the Company's FDA-cleared 12-lead ECG system for arrhythmia assessment Will lead the Company's broader commercialization strategy across key growth initiatives, including heart attack detection and the 12-lead ECG extended-wear patch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strate

    1/22/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer

    Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at Regeneron Most recently served as Chief Marketing Officer, Global Ophthalmology at Merck BEDFORD, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that David W. Robinson has agreed to join the Company as Global Chief Commercial Officer. The appointment of Mr. Robinson, a proven commercial leader with a history of launching category-defining therapies, strategically positions Ocular for success

    1/21/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Soluna Appoints Michael Picchi as Chief Financial Officer

    Interim CFO David Michaels to remain on Soluna's Board following interim period Soluna Holdings, Inc. ("Soluna" or the "Company") (NASDAQ:SLNH), a developer of green data centers for intensive computing applications, including Bitcoin mining and AI, today announced it has appointed Michael Picchi as Chief Financial Officer and Treasurer, effective April 1, 2026. Picchi will lead Soluna's finance organization and support the Company's capital strategy as it scales its behind-the-meter, renewable-powered data center model and expands into Al. David Michaels, a member of Soluna's Board of Directors, has served as Interim Chief Financial Officer and Treasurer since August 2025. Michaels wil

    1/20/26 7:30:00 AM ET
    $SLNH
    EDP Services
    Technology

    $ACOR
    $AVCT
    $BEAT
    $BNRG
    Financials

    Live finance-specific insights

    View All

    Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations

    Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to host an investor webcast on Monday, March 2, 2026, at 7:30 AM ET to discuss the Macula Society presentations BEDFORD, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will present detailed results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), at the 49th Macula Soc

    2/23/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 26, 2026. Details of the event and replay are as follows:Conference call details:Date:February 26, 2026Time:8:30 a.m. ETURL to register phone:Register HereDial-in number:(888) 880-3330 (U.S.) or(+1) (646) 357-8766 (International)Webcast:ir.novavax.com/eventsParticipants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants can als

    2/19/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD

    First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment Superiority primary endpoint met with 74.1% of subjects in the AXPAXLI™ arm maintaining vision at Week 36, a 17.5% risk difference (p=0.0006), compared to aflibercept (2 mg) arm 65.9% of subjects treated with AXPAXLI maintained vision at Week 52, a 21.1% risk difference (p<0.0001), compared to aflibercept (2 mg) arm Rescue-free rates in the AXPAXLI arm were 80.6%, 74.7%, and 68.8% at Weeks 24, 36, and 52 55.9% of subjects treated with AXPAXLI maintained CSFT within 30 μm from baseline at Week 36, a 17.1% risk difference (nominal p=0.0

    2/17/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AVCT
    $BEAT
    $BNRG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Brenmiller Energy Ltd

    SC 13D/A - Brenmiller Energy Ltd. (0001901215) (Subject)

    12/5/24 11:18:20 AM ET
    $BNRG
    Building Products
    Industrials

    SEC Form SC 13G filed by Ensysce Biosciences Inc.

    SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)

    11/14/24 5:52:56 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 5:49:38 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care